Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Other uses of dexrazoxane : Savene, the first proven antidote against anthracycline extravasation injuries. / Langer, Seppo W; Jensen, Peter Buhl; Sehested, Maxwell.

I: Cardiovascular Toxicology, Bind 7, Nr. 2, 2007, s. 151-3.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Langer, SW, Jensen, PB & Sehested, M 2007, 'Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries', Cardiovascular Toxicology, bind 7, nr. 2, s. 151-3. https://doi.org/10.1007/s12012-007-0021-5

APA

Langer, S. W., Jensen, P. B., & Sehested, M. (2007). Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovascular Toxicology, 7(2), 151-3. https://doi.org/10.1007/s12012-007-0021-5

Vancouver

Langer SW, Jensen PB, Sehested M. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries. Cardiovascular Toxicology. 2007;7(2):151-3. https://doi.org/10.1007/s12012-007-0021-5

Author

Langer, Seppo W ; Jensen, Peter Buhl ; Sehested, Maxwell. / Other uses of dexrazoxane : Savene, the first proven antidote against anthracycline extravasation injuries. I: Cardiovascular Toxicology. 2007 ; Bind 7, Nr. 2. s. 151-3.

Bibtex

@article{dea721cbda2e4352933e8ed362778356,
title = "Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries",
abstract = "Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.",
keywords = "Animals, Anthracyclines/adverse effects, Antibiotics, Antineoplastic/adverse effects, Cardiovascular Agents/therapeutic use, Clinical Trials as Topic, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Heart Diseases/chemically induced, Humans, Mice, Razoxane/therapeutic use",
author = "Langer, {Seppo W} and Jensen, {Peter Buhl} and Maxwell Sehested",
year = "2007",
doi = "10.1007/s12012-007-0021-5",
language = "English",
volume = "7",
pages = "151--3",
journal = "Cardiovascular Toxicology",
issn = "1530-7905",
publisher = "Humana Press",
number = "2",

}

RIS

TY - JOUR

T1 - Other uses of dexrazoxane

T2 - Savene, the first proven antidote against anthracycline extravasation injuries

AU - Langer, Seppo W

AU - Jensen, Peter Buhl

AU - Sehested, Maxwell

PY - 2007

Y1 - 2007

N2 - Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.

AB - Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.

KW - Animals

KW - Anthracyclines/adverse effects

KW - Antibiotics, Antineoplastic/adverse effects

KW - Cardiovascular Agents/therapeutic use

KW - Clinical Trials as Topic

KW - Clinical Trials, Phase I as Topic

KW - Clinical Trials, Phase II as Topic

KW - Heart Diseases/chemically induced

KW - Humans

KW - Mice

KW - Razoxane/therapeutic use

U2 - 10.1007/s12012-007-0021-5

DO - 10.1007/s12012-007-0021-5

M3 - Review

C2 - 17652821

VL - 7

SP - 151

EP - 153

JO - Cardiovascular Toxicology

JF - Cardiovascular Toxicology

SN - 1530-7905

IS - 2

ER -

ID: 247891580